Comparative Pharmacology
Head-to-head clinical analysis: DIACOMIT versus LACOSAMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIACOMIT versus LACOSAMIDE.
DIACOMIT vs LACOSAMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Stiripentol is an anticonvulsant that potentiates GABAergic neurotransmission by acting as a positive allosteric modulator of GABA-A receptors and inhibiting GABA transaminase. It also inhibits CYP2C19 and other cytochrome P450 enzymes, thereby increasing plasma concentrations of concomitant antiepileptic drugs like clobazam.
Selectively enhances slow inactivation of voltage-gated sodium channels, stabilizing hyperexcitable neuronal membranes and inhibiting repetitive neuronal firing.
10 mg/kg/day orally in two divided doses; increase weekly by 10 mg/kg/day to 70 mg/kg/day or 3 g/day, whichever is lower.
Oral or IV: 50 mg twice daily initially; increase by 50 mg twice daily weekly to maintenance 100-200 mg twice daily. Maximum 200 mg twice daily.
None Documented
None Documented
Clinical Note
moderateLacosamide + Sulfisoxazole
"The serum concentration of Sulfisoxazole can be increased when it is combined with Lacosamide."
Clinical Note
moderateLacosamide + Fluconazole
"The serum concentration of Fluconazole can be increased when it is combined with Lacosamide."
Clinical Note
moderateLacosamide + Ketoconazole
"The serum concentration of Ketoconazole can be increased when it is combined with Lacosamide."
Clinical Note
moderateLacosamide + Delavirdine
Terminal elimination half-life: 13-20 hours; in severe renal impairment (CrCl <30 mL/min), half-life prolonged to 40-60 hours. Requires dose adjustment.
Terminal elimination half-life is approximately 13 hours (range 12–16 hours) in adults. Steady state achieved after 3 days with BID dosing.
Primarily renal excretion: 50% as unchanged drug, 30% as glucuronide conjugate, 20% via fecal/biliary routes.
Renal: approximately 95% (40% unchanged, remainder as O-desmethyl metabolite). Fecal: <5%.
Category C
Category C
Anticonvulsant
Anticonvulsant
"The serum concentration of Delavirdine can be increased when it is combined with Lacosamide."